Evaluation of Candida species and antifungal susceptibilities among children with invasive candidiasis

Turk Pediatri Arsivi

Volumn 52, Issue 3, 2017, Pages 145-153

  Sütçü, Murat ^a   Acar, Manolya ^a   Erköse Genç, Gonca ^a   Kökçü, İlknur ^a   Aktürk, Hacer ^a   Atay, Gürkan ^a   Hançerli Törun, Selda ^a   Salman, Nuran ^a   Erturan, Zayre ^a   Somer, Ayper ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Antifungal susceptibility; Child; Invasive candidiasis

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ABDOMINAL INFECTION; ADOLESCENT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CATHETER INFECTION; CHILD; CLAVISPORA LUSITANIAE; EMPYEMA; EPSILOMETER TEST; FEMALE; FUNGAL EXAMINATION; HUMAN; INFANT; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEONATAL INTENSIVE CARE UNIT; NEWBORN; NONHUMAN; PEDIATRIC INTENSIVE CARE UNIT; PNEUMONIA; RETROSPECTIVE STUDY; SURGICAL INFECTION; URINARY TRACT INFECTION; URINE CULTURE;

EID: 85031121455     PISSN: 13060015     EISSN: 13086278     Source Type: Journal    
DOI: 10.5152/TurkPediatriArs.2017.5291     Document Type: Article

References (29)

1. Tragiannidis A, Tsoulas C, Kerl K, Groll AH. Invasive candidiasis: update on current pharmacotherapy options and future perspectives. Expert Opin Pharmacother 2013; 14: 1515-28. [CrossRef]
2. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three year analysis. Clin Infect Dis 1999; 29: 239-44. [CrossRef]
3. Coello R, Charlett A, Ward V, et al. Device-related sources of bacteraemia in English hospitals-opportunities for the prevention of hospital acquired bacteraemia. J Hosp Infect 2003; 53: 46-57. [CrossRef]
4. Safdar N, Fine JP, Maki DG. Meta-analysis: methods for diagnosing intravascular device-related bloodstream infection. Ann Intern Med 2005; 142: 451-66. [CrossRef]
5. L. Saiman, E Ludington, M Pfaller, et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19: 319-24. [CrossRef]
6. Gültekin B, Eyigör M, Tiryaki Y, Kırdar S, Aydın N. Kan kültürlerinden izole edilen Candida suşlarında antifungal duyarlılığın ve bazı virülans faktörlerinin araştırılması ve RAPD-PCR ile genotiplendirilmesi. Mikrobiyol Bul 2011; 45: 306-17.
7. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-32. [CrossRef]
8. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; 4th Informational Supplement M27-S4. CLSI, Wayne, PA, 2012.
9. Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med 2015; 373: 1445-56. [CrossRef]
10. Palazzi DL, Arrieta A, Castagnola E, et al. Candida speci-ation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study. Pediatr Infect Dis J 2014; 33: 1294-6. [CrossRef]
11. Celebi S, Hacimustafaoglu M, Özdemir Ö. Nosocomial candidaemia in children: results of a 9-year study. Mycoses 2007; 51: 248-57. [CrossRef]
12. Comert F, Külah C, Aktas E. Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period. Mycoses 2006; 50: 52-7. [CrossRef]
13. İris-efe N, Ersöz-Arat M, Şimşek F. Yoğun bakım ünitelerinde yatan hastalardan izole edilen Candida türlerinin identifikasyonu ve antifungal duyarlılıklarının araştırılması. Klimik Dergisi 2008; 2: 61-4.
14. Acar A, Öncül O, Küçükardalı Y, et al. Yoğun bakım ünitelerinde saptanan Candida enfeksiyonlarının epidemi-yolojik özellikleri ve mortaliteye etki eden risk faktörleri. Mikrobiyol Bul 2008; 42: 451-61.
15. Çekin Y, Pekintürk N, Çekin AH. Evaluation of species distribution and antifungal resistance of Candida isolates from hospitalized patients. J Clin Anal Med 2015; 6: 8-11. [CrossRef]
16. Hazırolan G, Yıldıran D, Baran I, et al. Yatan hasta örnek-lerinden izole edilen Candida izolatlarının tür dağılımla-rının ve antifungal duyarlılık profillerinin değerlendirilmesi. Turk Hij Den Biyol Derg 2015; 72: 17-26. [CrossRef]
17. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010; 54: 3149-54. [CrossRef]
18. Bakır M, Cerikçioğlu N, Barton R. Epidemiyology of Candida in Turkish tertiary care hospital. APMIS 2006; 114: 601-10. [CrossRef]
19. Boschman CR, Bodnar UR, Tornatore MA, et al. Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob Agents Chemother 1998; 42: 734-8.
20. Barchiesi F, Colombo AL, McGough DA, Fothergill AW, Rinaldi MG. In vitro activity of itraconazole against flu-conazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. AntiMİKrob Agents Chemother 1994; 38: 1530-3. [CrossRef]
21. Tan TY, Tan AL, Tee NW, Ng LS. A Retrospective analysis of antifungal susceptibilities of candida bloodstream ıso-lates from singapore hospitals. Ann Acad Med Singapore 2008; 37: 835-40.
22. Çalışkan E, Dede A, Biten Güven G. Kan kültürlerinde saptanan Candida türlerinin dağılımı ve antifungal duyarlılıkları. ANKEM Derg 2013; 27: 25-30.
23. Öztürk T, Özseven AG, Sesli Çetin E, Kaya S. Kan kültürlerinden izole edilen Candida suşlarının tiplendirilmesi ve antifungal duyarlılıklarının araştırılması. Kocatepe Tıp Derg 2013; 14: 17-22.
24. Zaoutis TE, Benjamin DK, Steinbach WJ. Antifungal treatment in pediatric patients. Drug Resistance Updates 2005; 8: 235-45. [CrossRef]
25. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpo¬ints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn microbiol Infect Dis 2011; 69: 45-50. [CrossRef]
26. Yenisehirli G, Bulut N, Yenisehirli A, et al. In vitro susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey. Jundishapur J microbiol 2015; 8: 28057. [CrossRef]
27. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42: 244-51. [CrossRef]
28. Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14: 164-76. [CrossRef]
29. Etiz P, Kibar F, Ekenoğlu Y, et al. Kan kültürlerinden izole edilen Candida türlerinin dağılımının ve antifungal duyarlılıklarının retrospektif olarak değerlendirilmesi. AN-KEM Derg 2015; 29: 105-13.